Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
55%(6 trials)

Phase Distribution

Ph phase_1
6
50%
Ph phase_2
5
42%

Phase Distribution

6

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
6(54.5%)
Phase 2Efficacy & side effects
5(45.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(11)
Terminated(1)

Detailed Status

Completed11
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (54.5%)
Phase 25 (45.5%)

Trials by Status

completed1192%
withdrawn18%

Recent Activity

0 active trials
Showing 5 of 12
completed

Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

NCT03611101
completedphase_2

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

NCT03486912
completedphase_2

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

NCT03486899
completedphase_1

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

NCT04634149
withdrawnphase_1

A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants

NCT04649710
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03611101

Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

Completed
NCT03486912Phase 2

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

Completed
NCT03486899Phase 2

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

Completed
NCT04634149Phase 1

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

Completed
NCT04649710Phase 1

A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants

Withdrawn
NCT04493567Phase 1

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Completed
NCT03400163Phase 2

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Completed
NCT02413372Phase 2

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Completed
NCT03445208Phase 1

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Completed
NCT03674476Phase 1

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

Completed
NCT02097277Phase 2

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

Completed
NCT03198182Phase 1

A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12